Company profile
OncoVista Innovative Therapies, Inc.
OTC: OVIT · Healthcare · Medical - Pharmaceuticals
#1161 of 1,418 Healthcare companies by revenue
EA Score
——FH —DQ 23GM —SS 28
v0.1 · 25/100 weight · pillars only
↑ listing tenure, filing timeliness · ↓ return on assets, balance-sheet leverage
Methodology →Revenue TTM
$0
Rev growth YoY (TTM)
needs 8 qtrs
Net income (FY)
-$2.5M
Employees
2
as of 2026-08-30
Market cap
$2.4k
as of 2026-08-30
Financials — latest annual
SEC EDGAR · USD-normalizedConceptUSDNativeFY
Revenue$0$02014
Net income-$2.5M-$2.5M2014
Operating income-$2.5M-$2.5M2014
Total assets$12.5k$12.5k2014
Liabilities$5.7M$5.7M2014
Equity-$5.7M-$5.7M2014
Revenue trend
FY2011 – FY2014 · USD
FY11
FY11
FY12
FY13
FY14
Revenue by segment
No segmentation disclosed for this filer. n/a
The read
What is OncoVista Innovative Therapies, Inc.’s revenue?
OncoVista Innovative Therapies, Inc. booked $0 in FY2014 revenue — among the slowest-growing Healthcare companies we track, at a -Infinity% net margin.
Peers · Healthcare
Sienna Biopharmaceuticals, Inc.——eFFECTOR Therapeutics, Inc.——Global Hemp Group Inc.——Regnum Corp.——Cotinga Pharmaceuticals Inc.——ForU Holdings, Inc.——Neighbors
Bexar →Key facts
CEOAlexander L. Weis
SectorHealthcare
IndustryMedical - Pharmaceuticals
HeadquartersSan Antonio, TX
ExchangeOTC: OVIT
Employees2
IPO date2007-10-26
Financials: SEC EDGAR (XBRL), USD-normalized per IAS 21 · TTM/quarterly + segments: FMP from filed disclosures · Filings: EDGAR submissions. County headcount and EA Score are in progress — see docs/DATA_GAPS.md.